NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 17 January 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Dr Britta Stordal Present for all items
4. Michael Chambers Present for all items
5. Dr Mark Corbett Present for all items
6. Chamkhor Dhillon Present for all items
7. Dr Rob Forsyth Present for all items
8. Dr Natalie Hallas Present for all items
9. John Hampson Present for all items
10. Dr Nigel Langford Present for all items
11. Dr Steven Lloyd Present for all items
12. Iain McGowan Present for all items
13. Ugochi Nwulu Present for all items
14. Stella O’Brien Present for all items
15. Dr Arpit Srivastava Present for all items
16. Professor Matthew Stevenson Present for all items
17. Professor Paul Tappenden  Present for all items

NICE staff (key players) present

Jasdeep Hayre, Associate Director Present for all items

Jenna Dilkes, Associate Director Present for all items

Christian Griffiths, Heath Technology Assessment Adviser Present for all items

Lizzie Walker, Heath Technology Assessment Analyst Present for all items

Raphael Egbu, Heath Technology Assessment Analyst Present for all items

Natalie Spray, Programme Manager Present for all items

Jen Hacking, Medical Editor Present for all items

Heidi Livingstone, Public Involvement Adviser Items 1 to 4.1.3

Gemma Smith, Coordinator, Committee Operations Present for all items

Leah Kelly, Administrator, Technology Appraisals Present for all items

NICE staff (observers) present

Henry Edwards, Associate Director Present for all items

Ian Watson, Heath Technology Assessment Adviser – Methods Present for all items

Thomas Palmer, Technical Analyst, Interventional Procedures Present for all items

Miaoqing Yang, Technical Analyst, Methods and economics Present for all items

External assessment group representatives present

Nicole Downes, BMJ Group Items 1 to 4.1.3

Archie Walters, BMJ Group Items 1 to 4.1.3

Mariana Bacelar, BMJ Group Items 1 to 4.1.3

Steve Edwards, BMJ Group Items 1 to 4.1.3

Clinical & patient experts present

Dr Lisa Anderson Consultant Cardiologist and Chair Elect British Society for Heart Failure – clinical expert nominated by British Society for Heart Failure, Items 1 to 4.1.3

Nick Hartshorne-Evans, CEO of Pumping Marvellous Foundation - patient expert nominated by Pumping Marvellous Foundation, Items 1 to 4.1.3

Dr Andrew Ludman, Consultant Cardiologist – clinical expert nominated by British Cardiovascular Society (endorsed by Royal College of Physicians), Items 1 to 4.1.3

Sarah Worsnop, Patient expert nominated by Pumping Marvellous Foundation, Items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Alex Cale, Professor Andrew Renehan, Dr David Foreman, Iftab Akram, Dr Pedro Saramago Goncalves and Dr Prithwiraj Das.

### News and announcements

* 1. Committee welcomed new members Dr Britta Stordal (Public Health Specialist) and Dr Mark Corbett (HTA Specialist).

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 6 December 2022

### Appraisals of dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID1648] and empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID3945]

* 1. Part 1 – Closed session
		1. The chair welcomed the invited experts, external assessment group representatives, and company representatives from AstraZeneca and Boehringer Ingelheim.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared a financial interest as he has recently participated in some podcasts on Health Technology Assessment funded by Boehringer Ingelheim (BI), but these did not involve consideration of any BI products. It was agreed that his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Professor Matthew Stevenson declared a financial interest as he has received funding from AstraZeneca but not in relation to this appraisal. It was agreed that his declaration would not prevent Professor Stevenson from participating in discussions on this appraisal.
* Nominated clinical expert Dr Andrew Ludman declared direct financial & non-financial interests as he has received fees from AstraZeneca for teaching primary and secondary care health professionals around SGLT2i and dapagliflozin, he is also local principal investigator for the DAPA-MI clinical trial which is recruiting patients after a heart attack and randomising to placebo v dapagliflozin. It was agreed that his declaration would not prevent Dr Ludman from providing expert advice to the committee
* Nominated clinical expert Dr Lisa Anderson declared indirect interests as AstraZeneca signed a 2-year Joint Working agreement with the Endocrinology and Cardiology departments at St George’s Hospital in September 2020 to fund a weekly Cardiometabolic clinic for 2 years, she is not directly involved in the delivery of this service but as Heart Failure lead and is now working with the CCG to ensure long-term NHS funding for the clinic. It was agreed that her declaration would not prevent Dr Anderson from providing expert advice to the committee
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Matt Stevenson, Dr Steven Lloyd, and Ugochi Nwulu.
	1. Part 2 – Closed session (company representatives, experts and external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpages in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10942> & <https://www.nice.org.uk/guidance/indevelopment/gid-ta10946>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 14 February 2023 and will start promptly at 09.30.